Papadopoulos, Kyriakos P.

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 1,304

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 743

A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors

Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 543

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways

Cited by 431

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)

Ou, S.-H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., et al. (2022) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 322

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 305

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Bardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., et al. (2024) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 188

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology

Melanoma and MAPK PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 158

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Papadopoulos, K. P., Borazanci, E., Shaw, A. T., Katayama, R., Shimizu, Y., Zhu, V. W., Sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., et al. (2020) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy

Cited by 113

KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation

Johnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., et al. (2020) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 77

A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.

Shapiro, G., Rosen, L. S., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Kulanthaivel, P., et al. (2013) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 67

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Papadopoulos, K. P., Johnson, M. L., Lockhart, A. C., Moore, K., Falchook, G. S., Formenti, S. C., Naing, A., Carvajal, R. D., Rosen, L. S., Weiss, G. J., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 66

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment

Jänne, P. A., Bigot, F., Papadopoulos, K., Eberst, L., Sommerhalder, D., Lebellec, L., Voon, P. J., Pellini, B., Kalinka, E., Arbour, K., et al. (2023) · Molecular Cancer Therapeutics

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 63

A first-in-human phase I study of OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers

Tolcher, A., Flaherty, K., Shapiro, G. I., Berlin, J., Witzig, T., Habermann, T., Bullock, A., Rock, E., Elekes, A., Lin, C., et al. (2018) · The Oncologist

Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and Mutations

Cited by 57

Abstract CT232: clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 44

LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 42

Degradation of Macondo 252 oil by endophytic Pseudomonas putida

Zheng, M., Wang, W., Hayes, M., Nydell, A., Tarr, M. A., Van Bael, S. A., & Papadopoulos, K. (2018) · Journal of Environmental Chemical Engineering

Microbial bioremediation and biosurfactantsOil Spill Detection and Mitigation

Cited by 40

A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

Papadopoulos, K. P., Ou, S.-H. I., Johnson, M. L., Christensen, J., Velastegui, K., Potvin, D., Faltaos, D., & Chao, R. C. (2019) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 37

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

Tolcher, A. W., Bendell, J. C., Papadopoulos, K. P., Burris, H. A., Patnaik, A., Fairbrother, W. J., Wong, H., Budha, N., Darbonne, W. C., Peale, F., et al. (2016) · Clinical Cancer Research

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 33

Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer

Goldman, J. W., Gandhi, L., Patnaik, A., Rosen, L. S., Hilton, J. F., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies

Cited by 27

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

Vaena, D. A., Fleming, G. F., Chmielowski, B., Sharma, M., Hamilton, E. P., Sullivan, R. J., Shepard, D. R., Papadopoulos, K. P., Patnaik, A., ElNaggar, A., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 14

Abstract P5-19-13: clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer

Tolaney, S. M., Rosen, L. S., Beeram, M., Goldman, J. W., Gandhi, L., Tolcher, A. W., Papadopoulos, K. P., Rasco, D. W., Myrand, S. P., Kulanthaivel, P., et al. (2015) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 13